Measurement and Pharmacokinetics of Acetylsalicylic Acid by a Novel High Performance Liquid Chromatographic Assay

Cham, Bill E.; Ross-Lee, Lesley; Bochner, Felix; Imhoff, D M

doi:10.1097/00007691-198002040-00010

Cited by 30 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As can be seen from the table 2 that ASA contents of most of the samples formulated by the companies showed deviation from those determined in the laboratory, but were within the permissible limits. These results are in agreement with various reports on the active ASA contents in commercial aspirin preparation (Franeta et al, 2002, Salako et al, 1989, Cham, 1980. …”

Section: Acetylsalicylic Acid Contentssupporting

confidence: 93%

“…A stock solution containing 150 µg/ml (150 ppm) of acetylsalicylic acid was prepared by transferring 15 mg of the pure acetylsalicylic acid into 100ml volumetric flask and dissolved in a solution of 50% acetonitrile in water. From this stock solution a series of calibration solutions were prepared containing 20, 40, 60 and 80µg/ml acetylsalicylic acid in the same solvent and the calibration curve was drawn to calculate the concentration of ASA in various aspirin samples , Cham, 1980. …”

Section: High Performance Liquid Chromatography (Hplc)mentioning

confidence: 99%

See 1 more Smart Citation

Atomic Absorption Analysis of Toxic Heavy Metal Impurities in Various Commercial Aspirin Formulations

Al-Taeb¹

2015

View full text Add to dashboard Cite

Abstract:Aspirin is the most extensively used mild analgesic and antipyretic drug. In Libya as well as worldwide, aspirin is purchased without prescription in many forms and is imported into the country without any control. However, conditions for packing, storing and preventing the drug from damage are not properly followed. There are no supervision or quality control procedures on the validity and chemical composition of the drug. In this study, thirteen available aspirin forms imported from different countries and one sample from local factory were collected and analyzed for comparison. The quality of the samples was examined in terms of active ingredient (acetyl salicylic acid-ASA), toxic heavy metal and salicylic acid impurities. ASA contents were analyzed using volumetric titration and HPLC method. The toxic heavy metal impurities were determined using atomic absorption spectrophotometry, and salicylic acid impurity was determined by fluorimetric method. The active ASA contents were found in the range from 87 to 104%. Comparison of the determined ASA contents with the actual contents per tablet indicated that only 14% of the samples were in identical values, whereas; 57.1% were exceeded and 28.6% were less than the actual content per tablet. The salicylic acid impurities were under permissible limit. Although, the results for the toxic heavy metals impurities showed significant variations among the samples, but all were under the limit permitted by the world health organization.

show abstract

Section: Acetylsalicylic Acid Contentssupporting

confidence: 93%

Section: High Performance Liquid Chromatography (Hplc)mentioning

confidence: 99%

Atomic Absorption Analysis of Toxic Heavy Metal Impurities in Various Commercial Aspirin Formulations

Al-Taeb¹

2015

View full text Add to dashboard Cite

show abstract

“…Normal male baboons (Papio anubis) weighing [8][9][10][11][12][13][14] kg were used. All animals were dewormed and observed to be diseasefree for at least 6 wk before study.…”

Section: Methodsmentioning

confidence: 99%

“…The blood samples were treated with physostigmine during collection to prevent hydrolysis of aspirin to salicylic acid (12).…”

Section: Methodsmentioning

confidence: 99%

Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition.

Hanson¹,

Harker²,

Bjornsson³

1985

J. Clin. Invest.

120

View full text Add to dashboard Cite

To resolve questions of drug actions, efficacy, and interactions for platelet-modifying agents used clinically, we have compared the relative capacities and mechanisms of aspirin, dipyridamole, sulfinpyrazone, and dazoxiben to prevent arterial thromboembolism in a baboon model. In 136 studies the agents were given twice daily by oral administration both singly and in combination. The antithrombotic efficacy of a given therapy was determined by its capacity to interrupt steady-state platelet utilization induced by thrombogenic arteriovenous cannulae.When given alone, dipyridamole and sulfinpyrazone reduced the rate at which platelets were utilized by thrombus formation in a dose-dependent manner with essentially complete interruption by dipyridamole at 10 mg/kg per d. In contrast, neither aspirin (2-100 mg/kg per d) nor dazoxiben (20-100 mg/kg per d) decreased cannula platelet consumption detectably despite the striking reduction in the capacity of platelets to produce thromboxane B2. However, aspirin, but not dazoxiben, potentiated the antithrombotic effects of dipyridamole and sulfinpyrazone in a dose-dependent fashion without changing the pharmacokinetics for any of the agents. Complete potentiation required aspirin at 20 mg/kg per d to be given with each dose of dipyridamole. Because dazoxiben's blockade of platelet thromboxane A2 production was not associated with antithrombotic potentiation, and because complete potentiation by aspirin required a dose that fully inhibited vascular production of prostaglandin I2 (PGI2), we conclude that aspirin's potentiating effect on dipyridamole is independent of PGI2 production or inhibition of thromboxane A2 formation. In addition, because frequent repeated and synchronous dosing of aspirin was necessary, aspirin's potentiating effects appear to be produced by mechanism(s) unrelated to its potent, irreversible inhibition of platelet cyclooxygenase.

show abstract

“…study were similar to that found in other single dose aspirin studies (900 mg to 1,500 mg) with respect to AUC(SA), AUCu(SA), the apparent volume of distribution (V), peak SA plasma concentration (Cmax), time to peak (tmax) and SA clearance (CL(SA) etc. (Cham et al, 1980;Graham et al, 1977;Gunsberg et at., 1984;Roberts et al, 1983). Minor differences between the data sets can be attributed to variation in the mg kg71 dose, the age, sex and/or health status of the subjects involved in the various studies.…”

Section: Discussionmentioning

confidence: 99%

Salicylate pharmacokinetics in patients with rheumatoid arthritis.

Roberts

Friesen

et al. 1989

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 The pharmacokinetics of salicyclic acid (SA) and its major metabolite salicyluric acid (SU) were studied in nine patients with rheumatoid arthritis following a 900 mg oral dose of acetylsalicylic acid and during 6 weeks of chronic administration of enteric coated aspirin (3,900 mg day). Response to therapy was also monitored. 2 The various pharmacokinetic parameters determined in the study were similar to those observed in other single dose salicylate studies amongst healthy volunteers but were not predictive of salicylate concentration in the chronic dose study. 3 Plasma concentrations of SA (total and unbound) were found to decline significantly over the 6 weeks and plasma SU concentrations increased. 4 During the chronic dosing study, there was a significant increase in the Vmax (total and unbound) for the formation of SU, whilst the Km and SU clearance remained constant. Also, the elimination rate constant (k) for salicylate was not significantly affected. 5 Therapeutic response to salicylate therapy was not significantly affected by the decline in SA concentrations.

show abstract

Measurement and Pharmacokinetics of Acetylsalicylic Acid by a Novel High Performance Liquid Chromatographic Assay

Cited by 30 publications

References 0 publications

Atomic Absorption Analysis of Toxic Heavy Metal Impurities in Various Commercial Aspirin Formulations

Atomic Absorption Analysis of Toxic Heavy Metal Impurities in Various Commercial Aspirin Formulations

Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition.

Salicylate pharmacokinetics in patients with rheumatoid arthritis.

Contact Info

Product

Resources

About